Table I.

PICOS study selection criteria

Domain	Inclusion	Exclusion
Population	•Patients with asthma treated with biologics, including children and (young) adults	•Patients with asthma not treated with biologics
Interventions	• Licensed biologics, injected by patient and/or at home ○ Benralizumab ○ Dupilumab ○ Mepolizumab ○ Omalizumab ○ Reslizumab •Other biologics, if relevant	•Inhaled or oral asthma drugs
Comparators	•Licensed biologics, injected by patient and/or at home •Licensed biologics, regardless of location or person injecting •No comparator	•Inhaled or oral asthma drugs
Outcomes	• Clinical outcomes ○ Clinical measures (FEV1, FVC, blood eosinophil count) ○ Asthma symptoms/incidence of asthma exacerbation ○ Correct use ○ Adherence and compliance ○ Proportion with successful self-administration of biologic ○ Total number of AI administrations that failed ○ Reduction in OCS use ○ Safety: AE, SAE, systemic reactions, injection site reaction, self-reported pain, incidence of immunogenicity ○ Other as reported∗ • Humanistic burden ○ Patient preferences ○ Patient treatment experience ○ Patient confidence in using the AI ○ Injection fear ○ Quality of life (AQLQ, ACQ, ACT, EQ-5D, SGRQ, SF-36) ○ Other as reported∗ • Economic outputs ○ Total costs (sum of direct and indirect costs) ○ Direct costs • Doctor/hospital office • Nurse fees • Biologic Administration fees ○ Indirect costs • Work loss due to medical appointments • Opportunity loss due to medical appointments • Travel time and distance to appointments by medical setting (primary care physician, clinic, etc.) ○ Resource use • Physician visits • Specialist visits • Hospitalizations and length of stay • Emergency department visits ○ Others as reported∗	•Outcomes not related to (comparative evidence) self-administration of injectables
Study design	•All relevant (except exclusions)	•Nonrelevant narrative reviews, notes, commentaries, editorials, SLRs

EQ-5D, Euro-QoL-5D; FVC, forced vital capacity; SF-36, short form 36; SGRQ, St George’s Respiratory Questionnaire.

^∗Item listed under clinical, humanistic, and economic outcomes is not restrictive. Outcomes not listed but relevant for these broad topics can also be reasons to include publications.